JOP20200034A1 - تركيبة للتنشيط المتحكم فيه للمبيض - Google Patents

تركيبة للتنشيط المتحكم فيه للمبيض

Info

Publication number
JOP20200034A1
JOP20200034A1 JOP/2020/0034A JOP20200034A JOP20200034A1 JO P20200034 A1 JOP20200034 A1 JO P20200034A1 JO P20200034 A JOP20200034 A JO P20200034A JO P20200034 A1 JOP20200034 A1 JO P20200034A1
Authority
JO
Jordan
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
fsh
Prior art date
Application number
JOP/2020/0034A
Other languages
Arabic (ar)
English (en)
Inventor
Saez Joan-Carles Arce
Bjarke Mirner Klein
Lisbeth Helmgaard
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of JOP20200034A1 publication Critical patent/JOP20200034A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOP/2020/0034A 2017-09-01 2018-08-31 تركيبة للتنشيط المتحكم فيه للمبيض JOP20200034A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 COMPOSITION FOR CONTROLLED OVARIAN STIMULATION

Publications (1)

Publication Number Publication Date
JOP20200034A1 true JOP20200034A1 (ar) 2020-02-13

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0034A JOP20200034A1 (ar) 2017-09-01 2018-08-31 تركيبة للتنشيط المتحكم فيه للمبيض

Country Status (32)

Country Link
US (2) US11744879B2 (enExample)
EP (3) EP3973982B1 (enExample)
JP (2) JP6856819B2 (enExample)
KR (2) KR20250078595A (enExample)
CN (2) CN120617484A (enExample)
AR (1) AR112541A1 (enExample)
AU (1) AU2018326556B2 (enExample)
BR (1) BR112020003379A2 (enExample)
CA (1) CA3073624A1 (enExample)
CL (1) CL2020000482A1 (enExample)
DK (2) DK3675894T3 (enExample)
EA (1) EA202090480A1 (enExample)
ES (2) ES2904787T3 (enExample)
FI (1) FI3973982T3 (enExample)
HR (2) HRP20211802T1 (enExample)
HU (2) HUE068024T2 (enExample)
IL (1) IL272763B2 (enExample)
JO (1) JOP20200034A1 (enExample)
LT (2) LT3973982T (enExample)
MA (2) MA50034B1 (enExample)
MD (2) MD3973982T2 (enExample)
MX (2) MX2020002235A (enExample)
MY (1) MY200791A (enExample)
PH (1) PH12020500404A1 (enExample)
PL (2) PL3973982T3 (enExample)
PT (2) PT3675894T (enExample)
RS (2) RS62810B1 (enExample)
SG (1) SG11202003840QA (enExample)
SI (2) SI3973982T1 (enExample)
TW (1) TWI749255B (enExample)
UA (1) UA126869C2 (enExample)
WO (1) WO2019043143A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267608T1 (de) * 2000-01-27 2004-06-15 Applied Research Systems Verwendung von fsh zur behandlung von infertilität
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2700335C (en) * 2007-09-21 2015-12-01 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CA2945883A1 (en) * 2014-04-18 2015-10-22 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
MD3261661T2 (ro) 2015-02-26 2024-04-30 Ferring Bv Menotropină pentru tratarea infertilității
HUE048757T2 (hu) * 2015-04-17 2020-08-28 Ferring Bv FSH meddõség kezelésére
EP3286209B1 (en) 2015-04-24 2020-11-25 Ferring BV Method of production of gonadotrophin
AU2016282916B2 (en) 2015-06-26 2022-01-20 Ferring B.V. Methods of purification and/or viral inactivation
PL3787667T3 (pl) 2018-04-30 2025-07-28 Ferring B.V. Kompozycja do kontrolowanej stymulacji jajników
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
US20240024424A1 (en) 2024-01-25
IL272763B2 (en) 2024-02-01
CN111050787A (zh) 2020-04-21
PL3973982T3 (pl) 2024-11-04
AR112541A1 (es) 2019-11-06
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
EP4427806A2 (en) 2024-09-11
SG11202003840QA (en) 2020-05-28
RS65945B1 (sr) 2024-10-31
UA126869C2 (uk) 2023-02-15
FI3973982T3 (fi) 2024-09-23
CN120617484A (zh) 2025-09-12
JP2021046398A (ja) 2021-03-25
KR20250078595A (ko) 2025-06-02
HRP20211802T1 (hr) 2022-03-04
HUE056726T2 (hu) 2022-03-28
DK3973982T3 (da) 2024-09-23
HUE068024T2 (hu) 2024-12-28
SI3973982T1 (sl) 2024-10-30
MA56224B1 (fr) 2024-09-30
MX2024009224A (es) 2024-08-06
PT3675894T (pt) 2022-01-25
MA50034B1 (fr) 2022-02-28
PT3973982T (pt) 2024-09-16
MA50034A (fr) 2021-05-12
LT3973982T (lt) 2024-09-10
BR112020003379A2 (pt) 2020-08-25
SI3675894T1 (sl) 2022-01-31
EP4427806A3 (en) 2024-10-09
IL272763A (en) 2020-04-30
ES2989511T3 (es) 2024-11-26
TWI749255B (zh) 2021-12-11
CL2020000482A1 (es) 2020-06-26
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
EP3973982A1 (en) 2022-03-30
US20200197493A1 (en) 2020-06-25
US11744879B2 (en) 2023-09-05
EP3973982B1 (en) 2024-07-31
WO2019043143A1 (en) 2019-03-07
MY200791A (en) 2024-01-16
JP2020528071A (ja) 2020-09-17
MD3973982T2 (ro) 2024-11-30
AU2018326556A1 (en) 2020-03-05
MX2020002235A (es) 2020-07-20
AU2018326556B2 (en) 2024-09-26
TW201919687A (zh) 2019-06-01
PH12020500404A1 (en) 2021-03-01
MA56224A (fr) 2022-04-20
JP7373479B2 (ja) 2023-11-02
ES2904787T3 (es) 2022-04-06
KR20200045543A (ko) 2020-05-04
EP3675894B1 (en) 2021-11-03
EP3675894A1 (en) 2020-07-08
MD3675894T2 (ro) 2022-03-31
CA3073624A1 (en) 2019-03-07
HRP20241171T1 (hr) 2024-11-22
DK3675894T3 (da) 2022-01-24
RS62810B1 (sr) 2022-02-28
JP6856819B2 (ja) 2021-04-14

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
EP4218785A3 (en) Mitochondria-targeting peptides
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2014001489A (es) Composicion para la estimulacion ovarica controlada.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
PH12021550122A1 (en) Solubilized apyrases, methods and use
PH12017501300A1 (en) Novel iodophor composition and methods of use
PH12020550340A1 (en) Anti-pacap antibody
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12020500079A1 (en) Novel substituted xanthine derivates
EP3524257A4 (en) USE OF POLYPEPTIDE IN CONNECTION WITH EXCITATIVE NERVOUS INJURY IN THE PREVENTION, REDUCTION OR TREATMENT OF PAIN
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2021006102A (es) Suministro mejorado de agentes grandes.
PH12020500404A1 (en) Composition for controlled ovarian stimulation
MX2018002921A (es) Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2020011738A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MA53909B1 (fr) Compositions et méthodes de stimulation ovarienne contrôlée
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.
EP4371613A3 (en) Compounds for use in the treatment of ocular pain